Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08UGX
|
|||
| Former ID |
DNC008925
|
|||
| Drug Name |
LIAROZOLE
|
|||
| Synonyms |
Liarozole; Liazal; 115575-11-6; R-75251; LIAROZOLE FUMARATE; Liarozole [INN:BAN]; Liarozolum [INN-Latin]; Liarozol [INN-Spanish]; R 75251; R-61405; R085246; R 61405; R-085246; R 085246; 6-((3-chlorophenyl)(1H-imidazol-1-yl)methyl)-1H-benzo[d]imidazole; UNII-17NYD2210B; CHEMBL389433; UNII-090Y06W08H; 17NYD2210B; 090Y06W08H; Liarozolum; Liarozol; 1H-Benzimidazole, 5-((3-chlorophenyl)-1H-imidazol-1-ylmethyl)-; NCGC00181034-01; Liarozole, (-)-; Liarozole, (+)-; AC1L1TNN; AC1Q3M3B; SCHEMBL18597; GTPL5210; SCHEMBL15944205; DTXSID9048277
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Dermatological disease [ICD-11: DA24.Y] | Phase 2/3 | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H13ClN4
|
|||
| Canonical SMILES |
C1=CC(=CC(=C1)Cl)C(C2=CC3=C(C=C2)N=CN3)N4C=CN=C4
|
|||
| InChI |
1S/C17H13ClN4/c18-14-3-1-2-12(8-14)17(22-7-6-19-11-22)13-4-5-15-16(9-13)21-10-20-15/h1-11,17H,(H,20,21)
|
|||
| InChIKey |
UGFHIPBXIWJXNA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 115575-11-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:135316
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Aromatase (CYP19A1) | Target Info | Inhibitor | [3] |
| Cytochrome P450 26 (CYP26A1) | Target Info | Inhibitor | [4] | |
| BioCyc | Superpathway of steroid hormone biosynthesis | |||
| Estradiol biosynthesis II | ||||
| Estradiol biosynthesis I | ||||
| KEGG Pathway | Retinol metabolism | |||
| Metabolic pathways | ||||
| Steroid hormone biosynthesis | ||||
| Ovarian steroidogenesis | ||||
| NetPath Pathway | FSH Signaling Pathway | |||
| Panther Pathway | Androgen/estrogene/progesterone biosynthesis | |||
| Pathwhiz Pathway | Retinol Metabolism | |||
| Androgen and Estrogen Metabolism | ||||
| Reactome | Endogenous sterols | |||
| WikiPathways | Vitamin A and Carotenoid Metabolism | |||
| Metapathway biotransformation | ||||
| Oxidation by Cytochrome P450 | ||||
| Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
| Adipogenesis | ||||
| Phase 1 - Functionalization of compounds | ||||
| Tryptophan metabolism | ||||
| Ovarian Infertility Genes | ||||
| Metabolism of steroid hormones and vitamin D | ||||
| FSH signaling pathway | ||||
| Integrated Breast Cancer Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5210). | |||
| REF 2 | ClinicalTrials.gov (NCT00282724) Efficacy and Safety of Two Doses of Liarozole vs. Placebo for the Treatment of Lamellar Ichthyosis. U.S. National Institutes of Health. | |||
| REF 3 | Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. | |||
| REF 4 | Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells. Bioorg Med Chem. 2008 Sep 1;16(17):8301-13. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.